Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Merelbeke – page 16

1 667 clinical trials in Merelbeke, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Merelbeke at a glance
1 667
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 667 trials in Merelbeke

Open in trial search

Graves' disease

Recruiting

Long-Term Study of Imeroprubart in Adults With Graves' Disease

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Imeroprubart
  • Sponsor:Immunovant Sciences GmbH

IgA nephropathy

Recruiting

Long-Term Safety Study of Zigakibart in Adults with IgA Nephropathy Who Have Completed Previous Zigakibart Trials

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Zigakibart
  • Sponsor:Novartis Pharma AG

A study to evaluate the effect of EA-230 on the hospital stay length for patients undergoing coronary artery bypass surgery for coronary artery disease.

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:EA-230
  • Sponsor:EBI Anti Sepsis B.V.

A study to evaluate the efficacy and safety of DYNE-101 in patients with Myotonic Dystrophy Type 1

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Potassium Chloride
  • Sponsor:Dyne Therapeutics Inc.

A study to evaluate the safety and effectiveness of IKT-001 compared to a placebo in adults with pulmonary arterial hypertension.

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:IKT-001PRO
  • Sponsor:Inhibikase Therapeutics Inc.

A study on the effectiveness of cagrilintide and semaglutide for weight management in children and adolescents with obesity

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Ovarian cancer

Recruiting

A study of sacituzumab tirumotecan and bevacizumab in patients with newly diagnosed advanced ovarian cancer following first-line platinum-based chemotherapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Obesity+1

Recruiting

A study of eloralintide in adults with persistent obesity or overweight who are currently treated with a weekly incretin medication

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:LY3841136 sodium
  • Sponsor:Eli Lilly & Co.

A study to evaluate the safety and effectiveness of NIO752 in patients with progressive supranuclear palsy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:NIO752
  • Sponsor:Novartis Pharma AG

A study to evaluate the safety and how pivekimab sunirine works in children with relapsed or refractory acute myeloid leukemia

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Pivekimab Sunirine
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Bladder cancer

Recruiting

A study of sacituzumab tirumotecan versus docetaxel, paclitaxel, or vinflunine for patients with pretreated advanced or metastatic bladder cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer+1

Recruiting

Maintenance Therapy Study of Inavolisib with Pertuzumab and Trastuzumab in Patients with HER2‑Positive, PIK3CA‑Mutated Locally Advanced or Metastatic Breast Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Merelbeke

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical trials focusing on proton pump inhibitor (PPI) medication management in patients with chronic digestive conditions. This research explores optimal approaches for medication reduction in cases where long-term use may not be indicated.

  • Functional Dyspepsia
  • Gastroesophageal Reflux
  • Chronic Heartburn

The study evaluates different deprescribing strategies, including on-demand PPI use and alternative treatments with alginate formulations, aiming to improve patient care in primary healthcare settings.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.